Abstract P232 Table 1 Outcomes

Time Period:	MRC5 Patients Referred:	MRC5 Patients Recruited:	No. recruited to Full PR:	Completion of Full PR:	Attendance at all 4 Education Sessions:
Apr 15-Oct 15: (7 months)	11	6 (54%)	0 (0%)	0 (0%)	2 (33%)
Nov 15-Mar 16: (5 months)	14	9 (64%)	6 (67%)	5 (55%) (1 declined offer)	4 (44%)

The patient who did not complete full programme continued to attend education. 1 patient attended the first session with no further engagement. 1 patient deferred until June 2016. Qualitative data reports significant benefit.

This modified approach was observed during the RCP site visit. Feedback included the need for feedback to the BTS with regards to greater flexibility with the standards and their future developments as a consequence of observing our modified approach to PR.

What Next? Modification to standard PR offers significant improvement in attendance and completion of PR for patient with significant dyspnoea (MRC5). Could these results be replicated within other PR service?

We continue to offer modified PR and now include MRC4 patients with significant co-morbidities which would otherwise restrict attendance.

REFERENCES

- 1 National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care (CG101). London: NICE, 2010.
- 2 British Thoracic Society. *BTS guideline on pulmonary rehabilitation in adults*. London: BTS, 2013.

P233

A PILOT DIAGNOSTIC CARDIO-RESPIRATORY BREATHLESSNESS CLINIC: CAN A SYMPTOM-BASED APPROACH ACHIEVE AN EARLIER DIAGNOSIS?

¹I Valero-Sanchez, ¹S Khatri, ²W Nicolson, ¹H Seth, ¹R Walton, ³DP Jackson, ¹MC Steiner, ¹RA Evans. ¹Respiratory Department, Glenfield Hospital, Leicester, UK; ²Cardiology Department, Glenfield Hospital, Leicester, UK; ³Barwell Medical Centre, Leicester, UK

10.1136/thoraxjnl-2016-209333.376

Introduction We aimed to compare the time to diagnosis and treatment between a combined cardio-respiratory diagnostic breathlessness clinic (BC) and usual specialist outpatient care (UC) in patients with chronic breathlessness referred from primary care.

Methods We surveyed patients with undifferentiated chronic breathlessness referred to secondary care outpatient cardiology and respiratory services during March 2015 (UC). Subsequently, we implemented a fortnightly pilot breathlessness clinic (BC) between August 2015 and January 2016 using existing referrals to either cardiology or respiratory specialties. Patients were seen by either a consultant cardiologist or respiratory physician, reviewed by a physiotherapist, and discussed by the MDT at the end of clinic.

Abstract P233 Table 1 Results of a survey of usual specialist outpatient care (UC) versus a combined cardio-respiratory breathlessness clinic (BC)

	Usual care	Breathlessness clinic
Number	38	54
Age (yrs)	67 [15]	66 [17]
Gender	50% male	42% male
Time to be seen (weeks)	13 [8]	5 [3]
Time to diagnosis (weeks)	16 [7]	5 [8]
Time to physiotherapy (weeks)	19 [13]	1 [1]
% discharged after single follow up	35%	87%
Did Not Attend	18%	4%
Diagnoses (n)	COPD: 9 ILD: 6 Asthma: 5 Dysfunctional breathing: 4 Bronchiectasis: 3 OSA: 2 Bronchitis: 2 Other (respiratory): 4 Other (cardiology): 3	COPD: 8 ILD: 4 Asthma: 8 Dysfunctional breathing: 11 Bronchiectasis: 2 OSA: 1 Obesity and physical de-conditioning: 7 Heart Failure: 7 Arrhythmia: 2 Valvular heart disease: 3 Musculoskeletal chest pain: 1

The investigations performed in primary care were documented and where needed the following investigations were completed for the BC: haemoglobin, brain natriuretic peptide, spirometry, electrocardiogram, chest radiograph, Nijmegen questionnaire, screening for anxiety and depression symptoms and a physical activity questionnaire. Time to diagnosis, physiotherapy, treatment and discharge were measured and compared with UC. Patients were requested to complete a patient experience questionnaire.

Results Table 1 shows the results of UC compared to the BC. 35% of referrals from primary care reported ≤ 1 investigation and only 28% had had spirometry performed. The MRC dyspnea scale grade distribution in the BC was MRC1 = 4%, MRC2 = 30%, MRC3 = 37%, MRC4 = 22%, MRC5 = 7%. Co-morbidity was common with over >80% of patients having at least two diagnoses contributing to their breathlessness. Dysfunctional breathing was the commonest primary and secondary diagnosis.

18.5% of patients in the BC could have been diagnosed in primary care. 18.5% were originally referred to the incorrect specialty and in nearly 30% of patients referrals to the other specialty were potentially avoided due to the MDT discussion. Only one third of patients required specialist tests to secure their diagnosis. All patients rated their experience as 'excellent'.

Conclusions Our pilot diagnostic breathlessness clinic reduced time to diagnosis and treatment, and avoided further between-specialty outpatient appointments. However, our results demonstrate the need for symptom-based breathlessness pathways starting in primary care to utilise simple investigations prior to referral to specialist clinics.

REFERENCE

- 1 Valero I, et al. Abstract accepted ERS, 2016.

Understanding Airways and Blood Vessels in the Lung

P234 SPUTUM CYTOKINES AND CLINICAL BIOMARKERS IN SEVERE ASTHMA

R Shrimanker, S Go, S Thulborn, L Xue, ID Pavord. *Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK*

10.1136/thoraxjnl-2016-209333.377

Introduction Emerging treatments for type-2 high asthma such as anti-IL-5 (mepolizumab) and anti-IL-4 and IL-13 (dupilumab) target specific cytokine pathways resulting in type-2 inflammation. Whether patients with type 2 inflammation respond equally to both treatment or have distinct IL-13 and IL-5 profiles is currently unclear. We have tested the hypothesis that these pathways may function independently of each other and that simple biomarkers can help differentiate IL-13 and IL-5 high patients.

Methods Patients with well characterised, severe asthma were evaluated with the blood eosinophil count and fractional exhaled nitric oxide (FeNO). Patients also had paired measurements of type-2 cytokines in induced sputum samples. Sputum cytokines were measured using a Luminex assay.

Results We found that there was no relationship between the blood eosinophil count and FeNO. There was a positive correlation between FeNO and sputum IL-13 ($r = 0.51$, $p < 0.01$) and blood eosinophils and sputum IL-5 ($r = 0.47$, $p < 0.01$).

Conclusions These findings suggest that readily available, non-invasive biomarkers may be able to differentiate sub-phenotypes in type-2 high asthma. Post-hoc analysis of clinical trial data of anti-IL-5 and anti-IL-4 and IL-13 treatments based on the predominant clinical biomarker would be of interest to see if these predict response to treatment. Simple biomarkers may be of use in deciding which of the emerging biological treatments to use in severe, type-2 high asthma.

P235 EPIGENETIC LANDSCAPE OF THE ASTHMATIC AIRWAYS

¹P McErlan, ¹A Kelly, ²J Dhariwal, ¹J Watson, ³N Jurdzinski, ³J Smith, ²R Solari, ²MR Edwards, ³A Van Oosterhout, ²SL Johnston, ¹P Lavender. ¹Kings College, London, UK; ²Imperial College, London, UK; ³GlaxoSmithKline, Stevenage, UK

10.1136/thoraxjnl-2016-209333.378

The airway epithelium of asthmatics exhibits distinct genomic and phenotypic characteristics. However the mechanisms underlying the establishment and chronicity of these characteristics remains unknown. We investigated if epigenetic changes underpin the genomic characteristics of the asthmatic airways by determining the chromatin landscape of bronchial epithelial cells (BECs) in healthy and asthmatic adults.

We employed ChIP-seq of histone H3 acetylation (H3K27ac) to determine the chromatin landscape in *ex vivo* cultured BECs from healthy and allergic-atopic asthmatics ($n = 3$ donors each). Regions of differential enrichment were identified (MEDIPS) and associated genes and pathways determined (GREAT). Gene expression profiles were investigated by microarray (Illumina) and differential analysis conducted (Partek Genome Suite). Super enhancers (SEs) were identified (ROSE) and enrichment of transcription factor motifs (MEME) and their tissue distribution (protenatlas.org) determined.

We identified 33,744 differentially enriched regions (DERs) of H3K27ac between asthma and healthy BECs. DERs were associated with genes (e.g. SERPINB2, TSLP) and pathways (e.g. leukotriene synthesis, antiviral response) previously implicated in asthma and had little overlap with known glucocorticoid receptor binding sites (1.7% of total). DERs occurred up to 100kb from gene promoters and gain or loss of H3K27ac was associated with increased and decreased gene expression in asthmatics respectively. Using a comparative approach, we identified SEs that were common (i.e., present across all donors) and distinct to health and asthma. In addition to established asthma genes (e.g. CLCA1) and transcription factors (e.g. TP63), asthma-SEs encompassed non-coding RNAs (up to 32% of genes) and epithelial-specific transcription factors (e.g. GCM2) previously unreported in asthma.

Our data indicates that asthma influences the chromatin landscape of BECs and suggests the genomic differences observed in the asthmatic airway epithelium are underpinned by established epigenetic mechanisms.

P236 THE ROLE OF HISTONE ARGININE METHYLATION IN GENE EXPRESSION OF AIRWAY SMOOTH MUSCLE CELLS IN ASTHMA

KA Kaczmarek, RL Clifford, JK Patel, DE Shaw, J Dowden, AJ Knox. *University of Nottingham, Nottingham, UK*

10.1136/thoraxjnl-2016-209333.379

Introduction and objectives Asthma is estimated to affect at least 300 million people globally. About 25% of the patients do not respond to therapy; therefore we need to develop novel treatments. ASM cells have a crucial role in asthma, contributing to airway remodelling, inflammation and airflow obstruction. We have previously shown that epigenetic histone modifications, particularly histone lysine acetylation and methylation regulate the secretion of inflammatory mediators from ASM cells. Here we tested the hypothesis that histone arginine changes are also involved. Protein arginine N-methyltransferases (PRMTs) are the enzymes which catalyse histone arginine methylation (HRme, the addition of a methyl group to arginine residues on the N-terminal tails of histones), and inhibiting them represents a strategy to reduce the secretion of inflammatory mediators from ASM cells.

Methods Studies were performed in cultured human ASM cells from asthmatic and non-asthmatic donors at passage 6. PRMT expression in human ASM cells was investigated by qPCR. Protein levels of four PRMTs in human ASM cells were investigated by western blotting. As PMRT1 has previously been suggested to play a role in mouse asthma models, we studied the association of PRMT1 with eotaxin, IL-6, IP-10 and CXCL8 promoters in healthy ASM cells, under basal conditions and following stimulation with TNF- α (1ng/ml), by chromatin immunoprecipitation (ChIP). IgG was used as a negative control, while acetylated histone H4 (AcH4) was used as a positive control.

Results We found that ASM cells express the PRMT1, PRMT2, PRMT3, CARM1, PRMT5, PRMT6, PRMT7 and FBX011 mRNA and PRMT1, CARM1, PRMT5, and PRMT6 protein. The analysis showed no difference in the levels of expression between cells isolated from asthmatic and non-asthmatic donors.

Under basal conditions, PRMT1 was associated with all of the promoters and association increased following 1 hour stimulation with TNF- α .